Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.

Melodie Young, MSN, A/GNP-C, discusses how diagnosing prurigo nodularis can be challenging due to its similarity to other pruritic conditions, and highlights the importance of recognizing key features and patient subtypes with increased prevalence to accurately differentiate it from conditions like eczema and psoriasis.

Melodie Young, MSN, A/GNP-C, discusses how prurigo nodularis imposes a significant physical and mental burden on patients, with chronic itching, skin lesions, and emotional distress leading to a reduced quality of life and increased anxiety and depression.

Karan Lal, DO, MS, FAAD, discusses how to balance safety and efficacy considerations while promoting treatment adherence in young vitiligo patients, focusing on the unique challenges and monitoring requirements for this vulnerable population.

Karan Lal, DO, MS, FAAD, discusses how to optimize vitiligo management in pediatric patients through personalized treatment selection and age-appropriate counseling strategies that address both the physical and psychosocial aspects of the condition.

Karan Lal, DO, MS, FAAD, discusses how treatment approaches for vitiligo differ between adult and pediatric populations, with experts examining distinct patterns of care, therapeutic considerations, and clinical pearls specific to each age group.

Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.

Panelists discuss how patients with atopic dermatitis face numerous obstacles to optimal care, including limited access to specialists, high treatment costs, inadequate insurance coverage, and the need for more effective long-term management options.

Panelists discuss how atopic dermatitis presents and requires different management approaches across age groups, with distinct challenges in diagnosis, treatment adherence, and quality of life impacts between pediatric and adult populations.

Panelists discuss how a collaborative approach involving dermatologists, oncologists, and surgeons can optimize treatment outcomes and quality of life for patients with basal cell carcinoma through personalized, comprehensive care plans.

Panelists discuss how the primary endpoint of the Effisayil 2 trial focused on the time to first GPP flare, while secondary endpoints assessed flare severity, quality of life, and inflammatory markers, providing a comprehensive evaluation of spesolimab's impact on GPP management.

James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.